GlaxoSmithKline PLC (GSK)

GSK (NYSE:Drugs) EQUITY
$38.68
neg -0.07
-0.18%
Today's Range: 38.60 - 38.82 | GSK Avg Daily Volume: 2,750,100
Last Update: 08/21/17 - 3:45 PM EDT
Volume: 1,739,532
YTD Performance: 0.62%
Open: $38.76
Previous Close: $38.75
52 Week Range: $37.20 - $44.54
Oustanding Shares: 2,459,000,000
Market Cap: 96,023,950,000
6-Month Chart
TheStreet Ratings Grade for GSK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 4
Moderate Buy 0 0 0 0
Hold 4 4 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.89 1.89 1.75 1.86
Latest Dividend: 0.49
Latest Dividend Yield: 5.12%
Dividend Ex-Date: 08/09/17
Price Earnings Ratio: 22.44
Price Earnings Comparisons:
GSK Sector Avg. S&P 500
22.44 40.10 35.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-10.38% -12.90% -18.35%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.30 -0.20 -0.08
Net Income -89.50 -0.90 -0.48
EPS -91.00 -0.90 -0.50
Earnings for GSK:
EBITDA 9.07B
Revenue 34.26B
Average Earnings Estimates
Qtr (09/17) Qtr (12/17) FY (12/17) FY (12/18)
Average Estimate $0.83 $0.75 $2.85 $2.92
Number of Analysts 2 1 5 5
High Estimate $0.85 $0.75 $2.92 $3.00
Low Estimate $0.81 $0.75 $2.70 $2.86
Prior Year $0.83 $0.65 $2.78 $2.85
Growth Rate (Year over Year) 0.00% 15.38% 2.52% 2.53%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
The collapse of the Sino-American session on tariffs and access translates into market action for investors, and inaction on improved trade.
Bearish
Jul 05, 2017 | 9:08 AM EDT
GlaxoSmithKline was downgraded to "Neutral" from "Buy" at Citigroup.
Technical indicators suggest GSK can see further significant gains in 2017.
After another technical look at GSK, this FTSE component is still going strong.
There are nearly too many surging sectors to count.
Check out GSK's well developed base pattern.
These companies show signs of a change of direction.
Firms' 13F filings show how they've followed in the footsteps of the father of value investing.
As we all know, the stock market and the economy abhor uncertainty.
Stocks in the health care sector seem to have no underpinnings whatsoever.

Columnist Conversations

we will add this here to cheaply protect our downside a bit BOUGHT SPY SEP 244 PUT AT 2.70 ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.